AMGEN Inc
AMGEN Inc (AMGN) Option Chain
AMGEN Inc trades at $457.93, down 0.95%, with an IV Rank of 57.74%. This is average versus the past year, and the company carries a market cap of $247,700M in the Drug Manufacturers - General industry. On the Nov 20, 2026 chain, the at the money $457.50 strike shows calls at $4.15 / $7.15 and puts at $5.50 / $8.40, both carrying about $6.08 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $420.00 calls, at 1,356 contracts, and the $440.00 puts, at 250, as of Nov 17, 2026.
Read more
Tracking the AMGN option chain helps you see every strike and expiry on AMGEN Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AMGN options activity at a glance. Use our scanner to monitor the AMGN option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AMGN stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where AMGN options are being actively traded, and where they are not.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 32.35 | 45 | 4 | 3.27 | 5.43 | 7.10 | 10.30 | 452.50 | -1.19 | 2.80 | 7.00 | 0.00 | 4.90 | 2 | 40 | 67.65 |
| 40.28 | 198 | 13 | 4.04 | 2.93 | 5.30 | 8.65 | 455.00 | -0.64 | 3.90 | 7.60 | 0.00 | 5.75 | 10 | 61 | 59.72 |
| 48.60 | 47 | 6 | 5.22 | 0.43 | 4.15 | 7.15 | 457.50 | -0.09 | 5.50 | 8.40 | 0.00 | 6.95 | 13 | 81 | 51.40 |
| 56.93 | 589 | 43 | 4.20 | 0.00 | 2.00 | 6.40 | 460.00 | +0.45 | 6.50 | 9.90 | 2.07 | 6.13 | 12 | 1,528 | 43.07 |
| 64.92 | 58 | 0 | 3.23 | 0.00 | 1.05 | 5.40 | 462.50 | +1.00 | 8.15 | 11.40 | 4.57 | 5.21 | 10 | 239 | 35.08 |
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank57.74% Moderate
- Market cap (M$)247,700
- 52 weeks high-5.38%
- 52 weeks low46.59%
- Analyst recommendationHold
2.66 - Target price$440.54
-3.80% below the current stock price - Dividend—
- Payout ratio66.92%
- Earnings date2027-02-02
- P/E26.56
- Future P/E18.27
- EPS (ttm)17.24
- EPS growth next 5 years7.13%
As of Nov 17, 2026